Experimental models have shown ruboxistaurin, a PKCβ inhibitor, preserves kidney function by reducing urinary albumin excretion, reducing mesangial expansion and glomerulosclerosis and normalising tubulointerstitial fibrosis (Ishii et al., 1996; Kelly et al., 2007). Here, PRKCB is linked to glomerulosclerosis.